Valentín García-Gutiérrez1, Antonio Jiménez-Velasco2, M Teresa Gómez-Casares3, Fermín Sánchez-Guijo4, Jose Luis López-Sendón5, Juan Luis Steegmann Olmedillas6. 1. Servicio de Hematología, Hospital Universitario Ramón y Cajal, Madrid, España. Electronic address: jvalentingg@gmail.com. 2. Servicio de Hematología, Hospital Regional Universitario Carlos Haya, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España. 3. Servicio de Hematología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, España. 4. Servicio de Hematología, Instituto de Investigación Biomédica de Salamanca (IBSAL)-Hospital Universitario de Salamanca, Salamanca, España. 5. Servicio de Cardiología, Hospital Universitario La Paz, Madrid, España. 6. Servicio de Hematología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria (IIS-IP), Madrid, España.
Abstract
INTRODUCTION AND OBJECTIVES: The second generation tyrosine kinase inhibitors (TKI, dasatinib and nilotinib) used in chronic myeloid leukemia (CML) treatment have shown a benefit compared to imatinib in responses achieved and disease progression. However, both have been related to some cardiovascular toxicity, being more frequent in patients with cardiovascular risk factors (CVRFs). Nowadays, due to the lack of recommendations for CML patients, CVRF management is carried out heterogeneously. The aim of this work is to develop recommendations on the prevention and monitoring of cardiovascular events (CVD) in patients with CML treated with TKIs. MATERIAL AND METHODS: Experts from the Spanish Group of Chronic Myeloid Leukemia together with experts in cardiovascular risk have elaborated, after a consensus meeting, recommendations for the prevention and follow-up of CVE in patients with CML treated with TKI. RESULTS: Recommendations regarding the necessary information to be collected on clinical history, treatment decisions, as well as treatment and monitoring of CVRFs are shown in this document. CONCLUSIONS: TKI treatment requires comprehensive patient management from a multidisciplinary approach, in which both the prevention and management of CVRFs are essential.
INTRODUCTION AND OBJECTIVES: The second generation tyrosine kinase inhibitors (TKI, dasatinib and nilotinib) used in chronic myeloid leukemia (CML) treatment have shown a benefit compared to imatinib in responses achieved and disease progression. However, both have been related to some cardiovascular toxicity, being more frequent in patients with cardiovascular risk factors (CVRFs). Nowadays, due to the lack of recommendations for CML patients, CVRF management is carried out heterogeneously. The aim of this work is to develop recommendations on the prevention and monitoring of cardiovascular events (CVD) in patients with CML treated with TKIs. MATERIAL AND METHODS: Experts from the Spanish Group of Chronic Myeloid Leukemia together with experts in cardiovascular risk have elaborated, after a consensus meeting, recommendations for the prevention and follow-up of CVE in patients with CML treated with TKI. RESULTS: Recommendations regarding the necessary information to be collected on clinical history, treatment decisions, as well as treatment and monitoring of CVRFs are shown in this document. CONCLUSIONS: TKI treatment requires comprehensive patient management from a multidisciplinary approach, in which both the prevention and management of CVRFs are essential.
Authors: Ruth Stuckey; Juan Francisco López-Rodríguez; Santiago Sánchez-Sosa; Adrián Segura-Díaz; Nuria Sánchez-Farías; Cristina Bilbao-Sieyro; María Teresa Gómez-Casares Journal: World J Clin Oncol Date: 2020-12-24